C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia

被引:193
作者
Bakker, ABH
van den Oudenrijn, S
Bakker, AQ
Feller, N
van Meijer, M
Bia, JA
Jongeneelen, MAC
Visser, TJ
Bijl, N
Geuijen, CAW
Marissen, WE
Radosevic, K
Throsby, M
Schuurhuis, GJ
Ossenkoppele, GJ
de Kruif, J
Goudsmit, J
Kiuisbeek, AM
机构
[1] Crucell Holland BV, NL-2301 CA Leiden, Netherlands
[2] Free Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands
关键词
D O I
10.1158/0008-5472.CAN-04-1659
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) has a poor prognosis due to treatment-resistant relapses. A humanized anti-CD33 antibody (Mylotarg) showed a limited response rate in relapsed AML. To discover novel AML antibody targets, we selected a panel of single chain Fv fragments using phage display technology combined with flow cytometry on AML tumor samples. One selected single chain Fv fragment broadly reacted with AML samples and with myeloid cell lineages within peripheral blood. Expression cloning identified the antigen recognized as C-type lectin-like molecule-1 (CLL-1), a previously undescribed transmembrane glycoprotein. CLL-1 expression was analyzed with a human anti-CLL-1 antibody that was generated from the single chain Fv fragment. CLL-1 is restricted to the hematopoietic lineage, in particular to myeloid cells present in peripheral blood and bone marrow. CLL-1 is absent on uncommitted CD34(+)/ CD38(-) or CD34(+)/CD33(-) stem cells and present on subsets of CD34(+)/ CD38(+) or CD34(+)/CD33(+) progenitor cells. CLL-1 is not expressed in any other tissue. In contrast, analysis of primary AMLs demonstrated CLL-1 expression in 92% (68 of 74) of the samples. As an AML marker, CLL-1 was able to complement CD33, because 67% (8 of 12) of the CD33(-) AMLs expressed CLL-1. CLL-1 showed variable expression (10-60%) in CD34(+) cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia. The AML reactivity combined with the restricted expression on normal cells identifies CLL-1 as a novel potential target for AML treatment.
引用
收藏
页码:8443 / 8450
页数:8
相关论文
共 35 条
  • [1] Appelbaum F R, 2001, Hematology Am Soc Hematol Educ Program, P62
  • [2] High frequency of immunophenotype changes in acute myeloid leukemia at relapse:: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
    Baer, MR
    Stewart, GC
    Dodge, RK
    Leget, G
    Sulé, N
    Mrózek, K
    Schiffer, CA
    Powel, BL
    Kolitz, JE
    Moore, JO
    Stone, RM
    Davey, FR
    Carrol, AJ
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2001, 97 (11) : 3574 - 3580
  • [3] Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells
    Bakker, ABH
    Baker, E
    Sutherland, GR
    Phillips, JH
    Lanier, LL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) : 9792 - 9796
  • [4] Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments
    Boel, E
    Verlaan, S
    Poppelier, MJJG
    Westerdaal, NAC
    Van Strijp, JAG
    Logtenberg, T
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 239 (1-2) : 153 - 166
  • [5] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
    Bonnet, D
    Dick, JE
    [J]. NATURE MEDICINE, 1997, 3 (07) : 730 - 737
  • [6] CARON PC, 1992, CANCER RES, V52, P6761
  • [7] Chuang E, 1997, J IMMUNOL, V159, P144
  • [8] Colonna M, 2000, EUR J IMMUNOL, V30, P697
  • [9] New perspectives on recombinant human antibodies
    deKruif, J
    deVries, ARV
    Cilenti, L
    Boel, E
    vanEwijk, W
    Logtenberg, T
    [J]. IMMUNOLOGY TODAY, 1996, 17 (10): : 453 - 455
  • [10] SELECTION AND APPLICATION OF HUMAN SINGLE-CHAIN FV ANTIBODY FRAGMENTS FROM A SEMISYNTHETIC PHAGE ANTIBODY DISPLAY LIBRARY WITH DESIGNED CDR3 REGIONS
    DEKRUIF, J
    BOEL, E
    LOGTENBERG, T
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1995, 248 (01) : 97 - 105